[3976] in Athena User Interface
Hot watch for tomorrow morn with news after the close
daemon@ATHENA.MIT.EDU (K1thy)
Sat Aug 27 22:41:12 2005
Message-ID: <001101c5ab79$ed6a8220$a7691202@yrogw>
From: "K1thy" <K1thy@barwol.com>
To: <ffisher@mit.edu>
Date: Sat, 27 Aug 2005 19:41:01 -0800
MIME-Version: 1.0
Content-Type: multipart/alternative;
boundary="----=_NextPart_000_000E_01C5AB3F.410BAA20"
This is a multi-part message in MIME format.
------=_NextPart_000_000E_01C5AB3F.410BAA20
Content-Type: text/plain;
charset="iso-8859-1"
Content-Transfer-Encoding: quoted-printable
EMERGING =3D
GROWTH ALERT
Issue: 104361
August 2005
Worldwide Biotech & Pharmaceutical Co
Rapid Growth Alert
Symbol:
WWBP
52 Week
Range
2.00 - 11.00
Shares
Float:
25,000,000
Current
Price:
$3.73
12
Mo.Target Price
$22.00
Growth
Rating
High
Breaking News Alerts!
Up
0.73
(24.33%)
Get In While You Still Can!
Worldwide Biotech & Pharmaceutical Obtains the China Patent
Golden Medal For Its 'Intact Hepatitis C Virus (HCV) and Method for
Culturing HCV in Vitro by Cell Culture'
Thursday August 25, 9:00 am ET
Marks the Highest Award Over the Past 10
Years in the Biomedical Sciences Industry in China
XI'AN, China, Aug. 25 /Xinhua-PRNewswire/ -- Worldwide Biotech &
Pharmaceutical Company (OTC Bulletin Board: WWBP - News; ''WWBP'')
has obtained the China Patent Golden Medal for ''the Intact
Hepatitis C Virus (HCV) and Method for Culturing HCV in Vitro by
Cell Culture.''
ADVERTISEMENT
The project ''The Intact Hepatitis C Virus (HCV) and Method for
Culturing HCV in vitro by Cell Culture'' was awarded the Chinese
Patent by China Patent Bureau on October 23rd, 2002. The patent was
then awarded the prestigious China Patent Golden Medal (Chinese
Patent No. 01124001.6) in the 8th China Patent Assessment organized
by both General World Intellectual Property Organization (WIPO) and
the China Patent Office. Importantly, this patent was recognized by
the World Intellectual Property Organization (WIPO), issued as an
outstanding Chinese Patented Invention, and was the highest award
issued for achievements in the biomedical sciences industry over the
past 10 years in China.
''We are highly encouraged with our patent which is recognized by
the WIPO and it is such a great achievement for the whole company.
It's a great milestone,'' said WenXia Guo, CEO and President of WWBP,
''the success of this patented invention leads our company to a
worldwide market, we will continue our development and research of
new inventions and bring health to every customer.''
About World Intellectual Property
Organization (WIPO)
The World Intellectual Property Organization (WIPO) is an
international organization dedicated to promoting the use and
protection of works of the human spirit. These works -- intellectual
property -- are expanding the bounds of science and technology and
enriching the world of the arts. Through its work, WIPO plays an
important role in enhancing the quality and enjoyment of life, as
well as creating real wealth for nations. With headquarters in
Geneva, Switzerland, WIPO is one of the 16 specialized agencies of
the United Nations system of organizations. It administers 23
international treaties dealing with different aspects of
intellectual property protection.
About Worldwide Biotech & Pharmaceutical =3D
Company
Worldwide Biotech & Pharmaceutical Co. (''WWBP'') is a hi-tech
biotech company with top-ranking pharmaceutical R&D abilities, Good =
=3D
Manufacturing Practices (GMP) licensed manufacturing facilities and
a well-established marketing network in China and Southeast Asia.
The product range of WWBP covers Hepatitis C Virus (HCV) products,
diagnostic medicines and Over-The-Counter (OTC) drugs. WWBP
currently possesses 35,940 square meters of land and 5,359 square
meters of GMP standard facilities. With strong pharmaceutical R&D
abilities especially in the HCV field, WWBP has been known as the
first biotech company in the world to hold the technology of
culturing intact HCV in vitro by cell culture.
WWBP has achieved a GMP production scale level of 10,000 ml for
concentrated HCV material and 10 grams HCV antigen per month, which
is expected to bring WWBP considerable gross sale revenue each year
and greatly strengthen the company's R&D on anti-HCV drug screen =
=3D
and
HCV human vaccine. WWBP had successfully reached two Memoriam of
Understanding of Merger Agreements with pharmaceutical companies in
China, all of which have scalable production and well-established
sales networks, and the acquiring is expected to be finished before
the end of September 2005. The acquisitions will strengthen WWBP's
R&D abilities and production scale, as well as extend its marketing =
=3D
network throughout China and Southeast Asia. WWBP has been working
closely with pharmaceutical research institutes, and has established
connections with both central & local governments.
The Company, by and through our wholly owned =3D
subsidiary, Yangling Daiying Biotech and Pharmaceutical Group Co., Ltd., =
=3D
formerly Yangling Daiying Biotech Engineering Co., Ltd. (Daiying), a =3D
company incorporated on November 2001 in Shaanxi Province, China, has, =3D
effective on July 12, 2005, entered into an investment contract with Xian =
=3D
Jinyou Investment Management Co., Ltd. (Jinyou), for the purposes of =3D
forming a new company to be formed as a limited liability company pursuant =
=3D
to the laws and regulations of China, said company to be known as Shaanxi =
=3D
Daiying Medicine Distribution Co., Ltd. Pursuant to the Investment =3D
Agreement, both Daiying and Jinyou will invest a total of approximately =
=3D
$600,000 U.S. Dollars of which Daiying will invest $445,000 for 90 percent =
=3D
of Shaanxi Daiying and Jinyou will invest approximately $155,000 for 10 =
=3D
percent for Shaanxi Daiying. The new companys anticipated purpose is the =
=3D
wholesale distribution of traditional Chinese medicine, including Chinese =
=3D
medicine drink tablets, synthetic medicine, antibiotics, biotech medicine =
=3D
and biotech reagents; wholesale of Class II medical devices, Class III =3D
medical devices, including but not limited to, medical sewing materials =
=3D
and bond, medical high molecular materials and products, and disposable =
=3D
sterile medical devices. It takes about three months for the new company =
=3D
to apply for its business name at the Business Administrations office in =
=3D
China, and at said time said funds shall be funded. We believe that this =
=3D
new distribution company will broaden and strengthen our marketing and =3D
sales channels in the near future. A summary of significant accounting =3D
policies is included in Note 1 to the audited financial statements =3D
included Form 10-KSB as filed with the Securities and Exchange Commission =
=3D
for the year ended December 31, 2004. Management believes that the =3D
application of these policies on a consistent basis enables us to provide =
=3D
useful and reliable financial information about the company's operating =
=3D
results and financial condition. The Company expects if it is able to =3D
raise additional funds it will purchase additional equipment, otherwise, =
=3D
it will not. The Company further does not expect any significant change in =
=3D
the number of employees unless it accomplishes a merger with another =3D
company.
------=_NextPart_000_000E_01C5AB3F.410BAA20
Content-Type: text/html;;
charset="iso-8859-1"
Content-Transfer-Encoding: quoted-printable
<html>
<body>
<table width=3D"654" border=3D"1" align=3D"center" cellpadding=3D"0" =
cellspacing=3D"0" bordercolor=3D"#000000">
<tr>
<td width=3D"650"><table width=3D"650" border=3D"0" align=3D"center" =
cellpadding=3D"3" cellspacing=3D"0">
<tr bgcolor=3D"#003399">
<td colspan=3D"2" style=3D"padding:8px" height=3D"46" =
bgcolor=3D"#0000FF">
<p><font size=3D"4"><strong><font color=3D"#FFFFFF">EMERGING =
GROWTH ALERT</font></strong></p></td>
</tr>
<tr>
<td bgcolor=3D"#000000" style=3D"padding:2px">
<font color=3D"#FFFFFF">Issue: 104361</font></td>
<td bgcolor=3D"#000000" style=3D"padding:2px"><div =
align=3D"right">
<font color=3D"#FFFFFF">August 2005</font></div></td>
</tr>
<tr>
<td colspan=3D"2" style=3D"padding:10px"><div =
align=3D"left"></div>
<div align=3D"left"></div>
<table width=3D"325" border=3D"1" align=3D"right" =
cellpadding=3D"0" cellspacing=3D"0">
<tr>
<td><table width=3D"325" border=3D"1" align=3D"right" =
cellpadding=3D"3" cellspacing=3D"0">
<tr bgcolor=3D"#003399">
<td colspan=3D"2" bgcolor=3D"#0000FF"><b><em>
<font size=3D"2" face=3D"Arial, Helvetica, sans-serif" =
color=3D"#FFFFFF">
Worldwide Biotech & Pharmaceutical Co</font></em></b><font =
color=3D"#FFFFFF" size=3D"2" face=3D"Arial, Helvetica, =
sans-serif"><strong><br>
</strong></font><strong>
<font face=3D"Arial, Helvetica, sans-serif" size=3D"2" =
color=3D"#FFFFFF">
Rapid Growth Alert</font></strong></td>
</tr>
<tr>
<td width=3D"53%"><font size=3D"2" face=3D"Arial, =
Helvetica, sans-serif">
Sy<b></b>mbol: </font></td>
<td width=3D"47%"><em><b>
<font face=3D"Arial, Helvetica, sans-serif" =
size=3D"2">WWBP</font></b></em></td>
</tr>
<tr>
<td><font size=3D"2" face=3D"Arial, Helvetica, =
sans-serif">52 Week
Range</font></td>
<td>2.00 - 11.00</td>
</tr>
<tr>
<td><font size=3D"2" face=3D"Arial, Helvetica, =
sans-serif">Sha<b></b>res
Float: </font></td>
<td><font size=3D"2" face=3D"Arial, Helvetica, =
sans-serif">
25,000,000</font></td>
</tr>
<tr>
<td><font size=3D"2" face=3D"Arial, Helvetica, =
sans-serif">Current
Price:</font></td>
<td> <font size=3D"2" face=3D"Arial, Helvetica, =
sans-serif"><strong>
$3.73</strong></font></td>
</tr>
<tr>
<td><font size=3D"2" face=3D"Arial, Helvetica, =
sans-serif">12
Mo.Target Price</font></td>
<td><font size=3D"2" face=3D"Arial, Helvetica, =
sans-serif">$22.00</font></td>
</tr>
<tr>
<td><font size=3D"2" face=3D"Arial, Helvetica, =
sans-serif"> Growth
Rating</font></td>
<td>High</td>
</tr>
</table></td>
</tr>
</table>
<p><em>
<font color=3D"#FF0000" size=3D"4" face=3D"Arial, Helvetica, =
sans-serif"><strong>
Breaking News Alerts!<br>
<br>
</strong></font><strong>
<font face=3D"Arial, Helvetica, sans-serif" size=3D"4" =
color=3D"#FF0000">
Up</font><font face=3D"Arial, Helvetica, sans-serif" size=3D"4" =
color=3D"#CC0000">
</font></strong></em><b style=3D"color: #FF0000"><font size=3D"4">0.73
(24.33%)<br>
<br>
Get In While You Still Can!</font></b><em><strong><font face=3D"Arial, =
Helvetica, sans-serif" color=3D"#CC0000" size=3D"3"><br>
<br>
</font></strong><font size=3D"3" face=3D"Arial, Helvetica, sans-serif">
<b>Worldwide Biotech & Pharmaceutical Obtains the China Patent
Golden Medal For Its 'Intact Hepatitis C Virus (HCV) and Method for
Culturing HCV in Vitro by Cell Culture'</b></font><font size=3D"2" =
face=3D"Arial, Helvetica, sans-serif"><br>
<br>
<font color=3D"#FF0000">Thursday August 25, 9:00 am ET <br>
</font><br>
<font color=3D"#0000FF"><b>Marks the Highest Award Over the Past 10
Years in the Biomedical Sciences Industry in China</b> </font><br>
<br>
<br>
XI'AN, China, Aug. 25 /Xinhua-PRNewswire/ -- Worldwide Biotech &
Pharmaceutical Company (OTC Bulletin Board: WWBP - News; ''WWBP'')
has obtained the China Patent Golden Medal for ''the Intact
Hepatitis C Virus (HCV) and Method for Culturing HCV in Vitro by
Cell Culture.''<br>
ADVERTISEMENT<br>
<br>
<br>
The project ''The Intact Hepatitis C Virus (HCV) and Method for
Culturing HCV in vitro by Cell Culture'' was awarded the Chinese
Patent by China Patent Bureau on October 23rd, 2002. The patent was
then awarded the prestigious China Patent Golden Medal (Chinese
Patent No. 01124001.6) in the 8th China Patent Assessment organized
by both General World Intellectual Property Organization (WIPO) and
the China Patent Office. Importantly, this patent was recognized by
the World Intellectual Property Organization (WIPO), issued as an
outstanding Chinese Patented Invention, and was the highest award
issued for achievements in the biomedical sciences industry over the
past 10 years in China.<br>
<br>
''We are highly encouraged with our patent which is recognized by
the WIPO and it is such a great achievement for the whole company.
It's a great milestone,'' said WenXia Guo, CEO and President of WWBP,
''the success of this patented invention leads our company to a
worldwide market, we will continue our development and research of
new inventions and bring health to every customer.''<br>
<br>
<font color=3D"#0000FF"><b>About World Intellectual Property
Organization (WIPO)</b></font><br>
<br>
The World Intellectual Property Organization (WIPO) is an
international organization dedicated to promoting the use and
protection of works of the human spirit. These works -- intellectual
property -- are expanding the bounds of science and technology and
enriching the world of the arts. Through its work, WIPO plays an
important role in enhancing the quality and enjoyment of life, as
well as creating real wealth for nations. With headquarters in
Geneva, Switzerland, WIPO is one of the 16 specialized agencies of
the United Nations system of organizations. It administers 23
international treaties dealing with different aspects of
intellectual property protection.<br>
<br>
<font color=3D"#0000FF"><b>About Worldwide Biotech & Pharmaceutical =
Company</b></font><br>
<br>
Worldwide Biotech & Pharmaceutical Co. (''WWBP'') is a hi-tech
biotech company with top-ranking pharmaceutical R&D abilities, Good =
Manufacturing Practices (GMP) licensed manufacturing facilities and
a well-established marketing network in China and Southeast Asia.
The product range of WWBP covers Hepatitis C Virus (HCV) products,
diagnostic medicines and Over-The-Counter (OTC) drugs. WWBP
currently possesses 35,940 square meters of land and 5,359 square
meters of GMP standard facilities. With strong pharmaceutical R&D
abilities especially in the HCV field, WWBP has been known as the
first biotech company in the world to hold the technology of
culturing intact HCV in vitro by cell culture.<br>
<br>
WWBP has achieved a GMP production scale level of 10,000 ml for
concentrated HCV material and 10 grams HCV antigen per month, which
is expected to bring WWBP considerable gross sale revenue each year
and greatly strengthen the company's R&D on anti-HCV drug screen =
and
HCV human vaccine. WWBP had successfully reached two Memoriam of
Understanding of Merger Agreements with pharmaceutical companies in
China, all of which have scalable production and well-established
sales networks, and the acquiring is expected to be finished before
the end of September 2005. The acquisitions will strengthen WWBP's
R&D abilities and production scale, as well as extend its marketing =
network throughout China and Southeast Asia. WWBP has been working
closely with pharmaceutical research institutes, and has established
connections with both central & local governments.</font></p>
</ol> </em> </td>
</tr>
<tr>
<td colspan=3D"2" style=3D"padding:15px"><p align=3D"justify">
<font color=3D"#FFFFFF">The Company, by and through our wholly owned =
subsidiary, Yangling Daiying Biotech and Pharmaceutical Group Co., Ltd., =
formerly Yangling Daiying Biotech Engineering Co., Ltd. (Daiying), a =
company incorporated on November 2001 in Shaanxi Province, China, has, =
effective on July 12, 2005, entered into an investment contract with Xian =
Jinyou Investment Management Co., Ltd. (Jinyou), for the purposes of =
forming a new company to be formed as a limited liability company pursuant =
to the laws and regulations of China, said company to be known as Shaanxi =
Daiying Medicine Distribution Co., Ltd. Pursuant to the Investment =
Agreement, both Daiying and Jinyou will invest a total of approximately =
$600,000 U.S. Dollars of which Daiying will invest $445,000 for 90 percent =
of Shaanxi Daiying and Jinyou will invest approximately $155,000 for 10 =
percent for Shaanxi Daiying. The new companys anticipated purpose is the =
wholesale distribution of traditional Chinese medicine, including Chinese =
medicine drink tablets, synthetic medicine, antibiotics, biotech medicine =
and biotech reagents; wholesale of Class II medical devices, Class III =
medical devices, including but not limited to, medical sewing materials =
and bond, medical high molecular materials and products, and disposable =
sterile medical devices. It takes about three months for the new company =
to apply for its business name at the Business Administrations office in =
China, and at said time said funds shall be funded. We believe that this =
new distribution company will broaden and strengthen our marketing and =
sales channels in the near future. <br>A summary of significant accounting =
policies is included in Note 1 to the audited financial statements =
included Form 10-KSB as filed with the Securities and Exchange Commission =
for the year ended December 31, 2004. Management believes that the =
application of these policies on a consistent basis enables us to provide =
useful and reliable financial information about the company's operating =
results and financial condition. <br>The Company expects if it is able to =
raise additional funds it will purchase additional equipment, otherwise, =
it will not. The Company further does not expect any significant change in =
the number of employees unless it accomplishes a merger with another =
company. </font></p></td>
</tr>
</table></td>
</tr>
</table>
<br></body>
</html>
------=_NextPart_000_000E_01C5AB3F.410BAA20--
